Liquid droplet aerosols of nanoparticulate drugs
AssigneeElan Pharma International Limited
InventorsH. William Bosch, Kevin D. Ostrander, Eugene R. Cooper
Life of this patent
Estimating the term…
Abstract
There invention discloses aqueous dispersions of nanoparticulate aerosol formulations, dry powder nanoparticulate aerosol formulation, propellant-based aerosol formulations, methods of using the formulations in aerosol delivery devices, and methods of making such formulations. The nanoparticles of the aqueous dispersions or dry powder formulations comprise insoluble drug particles having a surface modifier on the surface thereof.
Claims28
An aerosol composition of an aqueous dispersion of nanoparticulate drug particles, wherein:
- (a) essentially each droplet of the aerosol comprises at least one nanoparticulate drug particle, wherein
- (i) the drug has a solubility in said aqueous dispersion of less than about 10 mg/mL;
- (ii) the drug is selected from the group consisting of, naproxen, triamcinolone acetonide, budesonide, and an anti-emetic;
- and
- (iii) the drug is present in a concentration of from about 0.05 mg/mL up to about 600 mg/mL;
- (b) the droplets of the aerosol have a mass median aerodynamic diameter (MMAD) less than or equal to about 100 microns;
- (c) the nanoparticulate drug particles have an effective average particle size of less than about 1000 nm, and have a surface modifier adsorbed on the surface of the drug, and
- (d) the aerosol composition can administer a drug dosage in less than about 15 seconds.
A method of administering to a patient an aerosol composition of an aqueous dispersion of nanoparticulate drug particles, wherein;
- (a) essentially each droplet of the aerosol comprises at least one nanoparticulate drug particle, wherein
- (i) the drug has a solubility in said aqueous dispersion of less than about 10 mg/mL;
- (ii) the drug is selected from the group consisting of naproxen, triamcinolone acetonide, budesonide, and an anti-emetic;
- and
- (iii) the drug is present in a concentration from about 0.05 mg/mL up to about 600 mg/mL;
- (b) the droplets of the aerosol have a mass median aerodynamic diameter (MMAD) less than or equal to about 100 microns;
- and
- (c) the nanoparticulate drug particles have an effective average particle size of less than about 1000 nm, and have a surface modifier adsorbed on the surface of the drug;
- and wherein the patient delivery time for the aerosol administration is about 15 seconds or less.
Dependencies are inferred from the claim text.